Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics reports clinical and corporate developments for a clinical-stage oncology business built around MasterKey therapies that target families of oncogenic mutations in cancer. Company news centers on silevertinib, a brain-penetrant fourth-generation EGFR MasterKey inhibitor, and its development in EGFR-mutant non-small cell lung cancer and glioblastoma.
Recurring updates include Phase 2 clinical data, medical meeting presentations, program expansion across NSCLC and GBM, financial results, cash runway commentary, partnership discussions and investor-conference participation. The company also describes its approach to genetically defined tumors, resistance mechanisms, wild-type mediated toxicities and central nervous system disease in program communications.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that David M. Epstein, Ph.D., President and CEO, will present at the Jefferies 2020 Virtual London Healthcare Conference. The event occurs on November 18, 2020, at 2:40 PM GMT/9:40 AM ET. The presentation will focus on the company's progress in developing precision oncology therapies targeting genetically defined cancers.
A live webcast is accessible via their investor relations page, with a replay available for three weeks post-event.
Black Diamond Therapeutics (Nasdaq: BDTX) reported significant progress in its Phase 1/2 clinical trial of BDTX-189, with the Phase 1 portion expected to complete by mid-2021. Financially, the company holds $333.1 million in cash as of September 30, 2020, sufficient to fund operations into 2023. The company also appointed Robert A. Ingram as Chairman and Rachel Humphrey, M.D., as Chief Medical Officer, enhancing its leadership. R&D expenses have increased to $12.9 million, reflecting growth initiatives.
Black Diamond Therapeutics (Nasdaq: BDTX) reported promising pre-clinical results for its lead candidate, BDTX-189, at the 32nd EORTC-NCI-AACR Virtual Symposium. The data indicate BDTX-189 can inhibit allosteric EGFR and HER2 mutations while sparing wild-type EGFR, potentially reducing toxicity. BDTX-189 showed effective tumor regression in various models, including patient-derived xenografts. The candidate is advancing to Phase 1/2 clinical trials (MasterKey-01) in patients with advanced solid tumors. BDTX-189 has received Fast Track designation from the FDA for specific mutations in solid tumors.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the presentation of pre-clinical data for its lead candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics on October 25, 2020. BDTX-189 is designed as an irreversible small molecule inhibitor targeting oncogenic mutations in EGFR and HER2. This presentation may offer insights into treating genetically defined cancers, as no FDA-approved therapies currently exist for these specific mutations. The findings could represent a significant advancement in precision oncology.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced the appointment of Robert A. Ingram as Chairman of its Board of Directors, succeeding founding Chairman Brad Bolzon, who will remain on the board. Ingram, a seasoned leader in the pharmaceutical industry with experience at GlaxoWellcome and GlaxoSmithKline, is expected to steer the company towards its goal of advancing precision oncology therapies. Black Diamond possesses a proprietary MAP platform aimed at targeting genetically defined cancers. The company is committed to transforming the oncology landscape through innovative small molecule therapies.
Black Diamond Therapeutics has appointed Robert A. Ingram as Chairman of its Board of Directors, effective immediately. Ingram, a notable figure in the pharmaceutical industry, previously served as CEO and Chairman of GlaxoWellcome and played a key role in forming GlaxoSmithKline. His experience is expected to bolster Black Diamond’s strategy in precision oncology, particularly in developing tumor-agnostic therapies. The company's MAP platform aims to identify and treat genetically defined cancers.
Black Diamond Therapeutics, a precision oncology company, announced that its CEO, David M. Epstein, Ph.D., will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 2:45 PM ET. The presentation aims to update on the company’s progress in developing small molecule, tumor-agnostic therapies for genetically defined cancers. A live webcast will be available on their investor relations website, with a replay accessible for three weeks. Black Diamond employs a proprietary MAP platform to target undrugged mutations in cancer.
Black Diamond Therapeutics announced the appointment of Rachel Humphrey, M.D. as Chief Medical Officer, effective immediately. Dr. Humphrey succeeds Karsten Witt, M.D., who will now serve as Senior Vice President of Non-Clinical Development. With extensive experience in oncology drug development, Dr. Humphrey joins from CytomX Therapeutics and has held senior roles at major pharmaceutical companies. Her leadership is expected to enhance the development of BDTX-189, an innovative inhibitor targeting oncogenic mutations across various cancers, which currently lacks a comparable FDA-approved treatment.
Black Diamond Therapeutics (BDTX) announced significant advancements regarding its lead candidate, BDTX-189, receiving FDA Fast Track designation for treating adult patients with specific solid tumors. The Phase 1/2 clinical trial is progressing as scheduled, with completion expected by mid-2021. Financially, the company reported a strong cash position of $345.0 million as of June 30, 2020, up from $39.7 million in Q2 2019. R&D expenses rose to $10.2 million, influenced by the trial's development, while G&A expenses also increased to $4.9 million.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a leader in precision oncology, announced that CEO David M. Epstein will present at two upcoming investor conferences. The presentations are scheduled for August 12, 2020, at the Wedbush PacGrow Healthcare Conference and August 13, 2020, at the Canaccord Genuity Growth Conference. Live webcasts will be available on the company’s website, with replays archived for three weeks. Black Diamond focuses on developing tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers.